Selective CETP Inhibition and PPARα Agonism Increase HDL Cholesterol and Reduce LDL Cholesterol in Human ApoB100/Human CETP Transgenic Mice

Abstract

Cholesteryl ester transfer protein (CETP) plays a key role in high-density lipoprotein (HDL) cholesterol metabolism, but normal mice are deficient in CETP. In this study, transgenic mice expressing both human apolipoprotein B 100 (ApoB-100) and human CETP (hApoB100/hCETP) were used to characterize the effects of CETP inhibition and peroxisome proliferator—activated receptor α (PPARα) agonism on lipid profiles. Torcetrapib (3, 10, and 30 mg/kg), a CETP inhibitor, fenofibrate (30 mg/kg), a weak PPARα agonist, and GW590735 (3 and 10 mg/kg), a potent and selective PPARα agonist were given orally for 14 days to hApoB100/hCETP mice and lipid profiles were assessed. The average percentages of HDL, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) cholesterol fractions in hApoB100/hCETP mice were 34.8%, 61.6%, and 3.6%, respectively, which is similar to those of normolipidemic humans. Both torcetrapib and fenofibrate significantly increased HDL cholesterol and reduced LDL cholesterol, and there was a tendency for torcetrapib to reduce VLDL cholesterol and triglycerides. GW590735 significantly increased HDL cholesterol, decreased LDL and VLDL cholesterol, and significantly reduced triglycerides. Maximal increases in HDL cholesterol were 37%, 53%, and 84% with fenofibrate, torcetrapib, and GW590735, respectively. These results, in mice that exhibit a more human-like lipid profile, demonstrate an improved lipid profile with torcetrapib, fenofibrate, and GW590735, and support the use of selective PPARα agonism for the treatment of lipid disorders. In addition, these data demonstrate the use of hApoB100/hCETP transgenic mice to identify, characterize, and screen compounds that increase HDL cholesterol.

Keywords

CETP cholesterol dyslipidemia PPARα transgenic mice

References

Grass DS , Saini U. , Felkner RH , et al. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J Lipid Res. 1995;36(5):1082-1091.

Paigen B. , Ishida BY , Verstuyft J. , Winters RB , Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis. 1990;10(2):316-323.

Hesler CB , Swenson TL , Tall AR Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem. 1987;262(5):2275-2282.

Jarnagin AS , Kohr W. , Fielding C. Isolation and specificity of a Mr 74,000 cholesteryl ester transfer protein from human plasma. Proc Natl Acad Sci U S A. 1987;84(7):1854-1857.

Tall AR Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34(8):1255-1274.

Bisgaier CL , Siebenkas MV , Brown ML , et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res. 1991;32(1):21-33.

Inazu A. , Brown ML , Hesler CB , et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323(18):1234-1238.

Young SG Recent progress in understanding apolipoprotein B. Circulation . 1990;82(5):1574-1594.

Tyroler HA Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation. 1987;76(3): 515-522.

10.

Naik SU , Wang X. , Da Silva JS , et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113(1):90-97.

11.

Hernandez M. , Wright SD , Cai TQ Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun. 2007;355(4):1075-1080.

12.

Clark RW Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors . Curr Opin Pharmacol. 2006;6(2): 162-168.

13.

Schaefer EJ , Asztalos BF Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006;17(4):394-398.

14.

Fruchart JC , Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006;42(1):39-64.

15.

Robillard R. , Fontaine C. , Chinetti G. , Fruchart JC , Staels B. Fibrates. Handb Exp Pharmacol. 2005(170):389-406.

16.

van der Hoogt CC , de Haan W. , Westerterp M. , et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007;48(8):1763-1771.

17.

Guerin M. , Bruckert E. , Dolphin PJ , Turpin G. , Chapman MJ Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 1996; 16(6):763-772.

18.

Guerin M. , Le Goff W. , Frisdal E. , et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab. 2003;88(8):3738-3746.

19.

Homma Y. , Ozawa H. , Kobayashi T. , et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia . Atherosclerosis. 1994; 106(2):191-201.

20.

Sierra ML , Beneton V. , Boullay AB , et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695.

21.

Duez H. , Chao YS , Hernandez M. , et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem. 2002;277(50): 48051-48057.

22.

Kooistra T. , Verschuren L. , de Vries-van der Weij J. , et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol. 2006;26(10):2322-2330.

23.

Hsueh W. , Abel ED , Breslow JL , et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res. 2007; 100(10):1415-1427.

24.

Okamoto H. , Yonemori F. , Wakitani K. , Minowa T. , Maeda K. , Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406(6792):203-207.

25.

Morehouse LA , Sugarman ED , Bourassa PA , et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48(6):1263-1272.

26.

Kothari HV , Poirier KJ , Lee WH , Satoh Y. Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis. 1997;128(1):59-66.

27.

Okamoto H. , Iwamoto Y. , Maki M. , Sotani T. , Yonemori F. , Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol. 2003;466(1-2):147-154.

28.

Cho KH , Shin YW , Choi MS , Bok SH , Jang SH , Park YB In vivo effects of CETP inhibitory peptides in hypercholesterolemic rabbit and cholesteryl ester transfer protein-transgenic mice. J Biochem Mol Biol. 2002;35(2):172-177.

29.

Clark RW , Sutfin TA , Ruggeri RB , et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib . Arterioscler Thromb Vasc Biol. 2004;24(3):490-497.

30.

Brousseau ME , Schaefer EJ , Wolfe ML , et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350(15):1505-1515.

31.

Barter PJ , Caulfield M. , Eriksson M. , et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-2122.

32.

Tall AR , Yvan-Charvet L. , Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007;27(2):257-260.

33.

Nissen SE , Tardif JC , Nicholls SJ , et al. Effect of torcetrapib on the progression of coronary atherosclerosis . N Engl J Med. 2007;356(13):1304-1316.

34.

Riserus U. , Sprecher D. , Johnson T. , et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes. 2008;57(2):332-339.